Sorafenib, the first approved agent for patients with advanced HCC in 2007, is a multikinase inhibitor that can target several protein receptors (VEGFR, PDGFR, KIT, and RET) to block vascular angiogenesis as well as inhibit several cell signaling pathways (Raf-1, B-Raf, and Ras/Raf/MEK/ERK) to impair tumor proliferation (7). The gene discussed is RAF1; the disease is hepatocellular carcinoma.